{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:45:06Z","timestamp":1787579106996,"version":"build-2736575974"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.2169\/internalmedicine.8784-21","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T22:08:37Z","timestamp":1642025317000},"page":"2367-2371","source":"Crossref","is-referenced-by-count":3,"title":["A Rare Case of Ankylosing Spondylitis Coexisting with Relapsing Polychondritis, Antiphospholipid Syndrome, and Myelodysplastic Syndrome"],"prefix":"10.2169","volume":"61","author":[{"given":"Hanna","family":"Park","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung","family":"Gon Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Uk","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 369: 1379-1390, 2007.","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. McAdam LP, O&apos;Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 55: 193-215, 1976.","DOI":"10.1097\/00005792-197605000-00001"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vitale A, Sota J, Rigante D, et al. Relapsing polychondritis: an update on pathogenesis, clinical features, diagnostic tools, and therapeutic perspectives. Curr Rheumatol Rep 18: 3, 2016.","DOI":"10.1007\/s11926-015-0549-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199, 1982.","DOI":"10.1111\/j.1365-2141.1982.tb08475.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27: 361-368, 1984.","DOI":"10.1002\/art.1780270401"},{"key":"6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1288\/00005537-197906000-00009","volume":"89","author":"JM Damiani","year":"1979","unstructured":"6. Damiani JM, Levine HL. Relapsing polychondritis--report of ten cases. Laryngoscope 89: 929-946, 1979.","journal-title":"The Laryngoscope","ISSN":"https:\/\/id.crossref.org\/issn\/0023-852X","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306, 2006.","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Azevedo VF, Galli NB, Kleinfelder AD, D&apos;Ippolito JF, Gulin Tolentino A, Paiva E. Relapsing polychondritis in a patient with ankylosing spondylitis using etanercept. Case Rep Rheumatol 2014: 353782, 2014.","DOI":"10.1155\/2014\/353782"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Bahiri R, Bzami F, Benbouazza K, Saoud B, Hajjaj-Hassouni N. Relapsing polychondritis and ankylosing spondylitis in the same patient. Joint Bone Spine 73: 482-484, 2006.","DOI":"10.1016\/j.jbspin.2005.12.011"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hernandez MV, Ruiz-Esquide V, Gomez-Caballero ME, Gomez-Puerta JA, Canete JD, Sanmarti R. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists? Rheumatology (Oxford) 50: 1523-1525, 2011.","DOI":"10.1093\/rheumatology\/ker144"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yi NH, Park SW, Park IS, Park CH, Lee CW. A case of relapsing polychondritis associated with ankylosing spondylitis. J Rheum Dis 22: 56-60, 2015.","DOI":"10.4078\/jrd.2015.22.1.56"},{"key":"12","unstructured":"12. Pazirandeh M, Ziran BH, Khandelwal BK, Reynolds TL, Khan MA. Relapsing polychondritis and spondyloarthropathies. J Rheumatol 15: 630-632, 1988."},{"key":"13","unstructured":"13. Carter JD. Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol 32: 1413, 2005."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lahmer T, Knopf A, Treiber M, Heemann U, Thuermel K. Treatment of relapsing polychondritis with the TNF-alpha antagonist adalimumab. Clin Rheumatol 29: 1331-1334, 2010.","DOI":"10.1007\/s10067-010-1488-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 43: 626-632, 2004.","DOI":"10.1093\/rheumatology\/keh136"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dion J, Costedoat-Chalumeau N, Sene D, et al. Relapsing polychondritis can be characterized by three different clinical phenotypes: analysis of a recent series of 142 patients. Arthritis Rheumatol 68: 2992-3001, 2016.","DOI":"10.1002\/art.39790"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Van Besien K, Tricot G, Hoffman R. Relapsing polychondritis: a paraneoplastic syndrome associated with myelodysplastic syndromes. Am J Hematol 40: 47-50, 1992.","DOI":"10.1002\/ajh.2830400110"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hammitzsch A, Lorenz G, Moog P. Impact of Janus kinase inhibition on the treatment of axial spondyloarthropathies. Front Immunol 11: 591176, 2020.","DOI":"10.3389\/fimmu.2020.591176"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80: 1004-1013, 2021.","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1: 5, 2013.","DOI":"10.1186\/2050-7771-1-5"},{"key":"21","unstructured":"21. U.S. Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication - FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death [Internet]. [cited 2021 Nov 19]. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 65: 1600-1607, 2013.","DOI":"10.1002\/acr.22039"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J 39: 3608-3614, 2018.","DOI":"10.1093\/eurheartj\/ehx145"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_8784-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T03:15:17Z","timestamp":1659755717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_8784-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":23,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8784-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"8784-21"}}